A new combination treatment for a type of lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma, with a specific 'other' genetic subtype
- Your tumor cells must have high levels of both MYC (at least 40%) and BCL2 (at least 50%) proteins
- You must have at least one tumor that can be measured on a CT or MRI scan (at least 1.5 cm across)
- You must not have received any prior treatment for lymphoma
- Your liver, kidney, and overall health must meet certain blood test and performance status criteria
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This study tests combining the drug lenalidomide with a standard chemotherapy regimen (G-CHOP) for people newly diagnosed with a specific type of lymphoma that has both aggressive and slow-growing parts. The goal is to see if this combination works better than standard treatment alone.
This trial tests a new combination of drugs (chidamide, lisaftoclax, and standard chemotherapy) to treat a serious type of blood cancer called double-hit or triple-hit diffuse large B-cell lymphoma. The goal is to see if adding these newer drugs to standard treatment improves how well the cancer responds.
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
This Phase 2 trial tests chidamide plus CHOP chemotherapy in people who have not received any prior treatment for a certain type of peripheral T-cell lymphoma. The study aims to shrink the lymphoma and improve outcomes while checking for side effects and safety.
Hear when a new Chidamide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.